Last updated: September 4, 2026
Lidocaine-tetracaine is a mature topical-local-anesthetic combination with limited product differentiation and low standalone revenue visibility. Its principal commercial forms are prescription creams and topical patches used to numb intact skin before needle procedures, dermatologic treatments, and minor interventions. The most established branded products are Pliaglis cream and Synera topical systems. Generic substitution, narrow clinical differentiation, and the absence of a clearly protected new chemical entity limit pricing power.
What products contain lidocaine and tetracaine?
The combination is delivered mainly through two technologies: a topical cream and a heated or oxygen-activated patch.
| Product |
Active ingredients |
Dosage form |
Principal use |
Regulatory status |
| Pliaglis |
Lidocaine 7%, tetracaine 7% |
Topical cream |
Temporary topical anesthesia before procedures |
FDA-approved prescription product |
| Synera |
Lidocaine 70 mg, tetracaine 70 mg |
Topical patch |
Temporary topical anesthesia before venipuncture or superficial procedures |
FDA-approved prescription product |
| Generic lidocaine-tetracaine products |
Usually 7%/7% cream or equivalent topical formulation |
Cream or topical system |
Local skin anesthesia |
Product-specific abbreviated or full approval pathways |
Pliaglis uses a peelable film-forming cream. The product is applied to intact skin, allowed to dry, and removed before the procedure. Synera uses a topical patch designed to facilitate drug delivery through heat and formulation technology. These delivery systems distinguish the combination from ordinary lidocaine cream, but neither active ingredient is novel.
How does lidocaine-tetracaine work?
Lidocaine and tetracaine are amide and ester local anesthetics, respectively. Both inhibit voltage-gated sodium channels and reduce nerve impulse transmission. Combining them can provide broader or stronger local anesthesia than a single agent, depending on concentration, residence time, and the delivery system.
The commercial value lies in delivery performance rather than pharmacological novelty. Relevant product characteristics include:
- speed of onset;
- depth and duration of dermal anesthesia;
- application time;
- ease of removal;
- skin irritation;
- systemic exposure;
- storage and handling requirements;
- compatibility with dermatology, cosmetic, pediatric, and vascular-access procedures.
A generic cream can compete effectively on price if the clinical procedure does not require the branded product's film-forming behavior or patch-based delivery.
What is the FDA regulatory status of lidocaine-tetracaine products?
Pliaglis and Synera were approved through the FDA's prescription-drug pathway rather than as over-the-counter products. The combination is regulated as a finished drug product, and approval depends on the specific formulation, dosage form, manufacturing process, labeling, and clinical data.
The principal regulatory distinction is between a generic formulation and a complex topical delivery system. A conventional cream may qualify for an abbreviated application if the applicant can satisfy the relevant pharmaceutical-equivalence and bioequivalence requirements. A patch or film-forming formulation may face greater development complexity because performance depends on drug release, adhesion, heat generation, and local absorption.
The FDA's Orange Book remains the key source for approved products, therapeutic-equivalence ratings, patent certifications, and exclusivity information. Pliaglis is associated with NDA 022140, while Synera is associated with NDA 021604. Orange Book status should be assessed at the product and NDA level because discontinued commercial availability does not by itself establish withdrawal for safety or efficacy reasons. [1]
What patents protect lidocaine and tetracaine products?
The active ingredients are long-established and do not have meaningful composition-of-matter exclusivity. Any remaining protection depends on formulation, delivery-system, manufacturing, or method-of-use claims.
Formulation patents
Historical patent protection has focused on:
- film-forming topical creams;
- eutectic or solvent systems;
- controlled release through a patch;
- thermal enhancement;
- adhesive layers and backing materials;
- combinations of local anesthetics;
- drying and removal characteristics.
Pliaglis was developed around a topical formulation that forms a removable film after application. Synera was developed around a delivery system that combines a patch with controlled heating and local anesthetic release. These claims can be commercially relevant even after basic active-ingredient patents expire, but their value depends on claim scope and whether generic manufacturers can design around them.
Method-of-use patents
Method-of-use claims may cover anesthesia before:
- venipuncture;
- intravenous cannulation;
- laser dermatology;
- tattooing or cosmetic procedures;
- superficial dermatologic surgery;
- injections and minor procedures.
Method claims generally provide narrower protection than product claims. Their enforceability also depends on product labeling, physician behavior, and the availability of non-infringing uses.
Manufacturing and process protection
Manufacturing barriers are more important for patches and film-forming products than for standard creams. A competitor may need validated processes for:
- uniform drug loading;
- patch adhesion;
- heat activation;
- packaging stability;
- solvent control;
- microbial limits;
- dose uniformity;
- removal without excessive skin trauma.
These factors can slow entry without creating durable exclusivity. They raise development and scale-up costs but usually do not prevent competition indefinitely.
When does lidocaine-tetracaine lose exclusivity?
The combination has already lost the principal exclusivity associated with its active ingredients. The practical exclusivity timeline is therefore product-specific.
| Exclusivity or protection category |
Commercial position |
| New chemical entity exclusivity |
Not applicable to lidocaine or tetracaine |
| Basic active-ingredient patents |
Expired or commercially immaterial |
| Original formulation patents |
Largely historical and dependent on claim status |
| Delivery-system patents |
Potentially relevant for patch and film products |
| Pediatric exclusivity |
Product-specific; not a general feature of the combination |
| Regulatory exclusivity |
Must be verified by NDA and approval history |
| Current protection |
Primarily formulation, device, manufacturing, and branding |
Exact patent expiration dates should be determined from the relevant patent family, terminal disclaimers, patent-term adjustments, and Orange Book listings. A single expiration date cannot be assigned to "lidocaine-tetracaine" as a combination because different products use different formulations and patent estates.
How many patents cover lidocaine-tetracaine?
There is no meaningful single patent count for the combination. Patent coverage must be separated into at least four groups:
- Pliaglis formulation and film patents.
- Synera patch, heat, and delivery patents.
- Generic formulation patents held by later entrants.
- Process and device patents that may not appear as active-drug patents.
Patent-count metrics can overstate competitive strength. A portfolio with several narrow claims may provide less protection than one broad, enforceable formulation claim. The relevant questions are whether a claim covers the commercial product, whether the patent remains unexpired, whether it is listed for the product, and whether a design-around is practical.
Which companies are challenging lidocaine-tetracaine products?
Competition is fragmented. The main challengers are generic-drug manufacturers, contract developers, specialty topical companies, and suppliers of alternative anesthetics.
Likely competitive groups include:
- generic manufacturers developing lidocaine-tetracaine creams;
- topical-drug companies selling lidocaine-only products;
- manufacturers of prilocaine-lidocaine creams;
- suppliers of injectable local anesthetics;
- medical-device companies selling needle-free or cooling-based anesthesia systems;
- compounding pharmacies serving procedural markets.
The closest pharmaceutical comparator is the lidocaine-prilocaine combination, commonly associated with EMLA. EMLA has a broader commercial history and a larger installed base in some procedural markets. Lidocaine-tetracaine products can compete through faster onset, higher local anesthetic loading, film formation, or patch convenience.
How does lidocaine-tetracaine compare with lidocaine-prilocaine?
| Factor |
Lidocaine-tetracaine |
Lidocaine-prilocaine |
| Main commercial formats |
Cream and patch |
Cream, generic cream, and related topical formats |
| Active-ingredient novelty |
Mature |
Mature |
| Differentiation |
Delivery system and local anesthetic combination |
Established clinical familiarity and broad generic availability |
| Generic pressure |
High |
High |
| Pricing power |
Greater for differentiated patches and proprietary films |
Lower for conventional creams |
| Main risk |
Substitution by lidocaine-only or prilocaine-lidocaine products |
Commoditization and broad generic competition |
| Regulatory complexity |
Higher for patches and film systems |
Lower for ordinary creams |
The combination's strongest commercial position is in settings where application convenience and predictable anesthesia matter more than the lowest acquisition cost. Its weakest position is in price-sensitive settings where ordinary lidocaine cream or compounded anesthetic can meet the clinical need.
What is the Orange Book status of lidocaine-tetracaine?
The Orange Book should be reviewed by NDA, proprietary name, dosage form, and active ingredient. Relevant products include Pliaglis and Synera, but listing status and patent information can change as products are discontinued, transferred, or removed from active marketing.
Orange Book review should address:
- whether the product is listed as prescription or discontinued;
- whether patents are listed;
- whether exclusivity remains;
- whether therapeutic-equivalence codes apply;
- whether a generic applicant has submitted a Paragraph IV certification;
- whether patents are subject to pediatric extensions or terminal disclaimers.
A formulation that is no longer actively marketed may still have historical Orange Book relevance, but its commercial value is lower if physicians, distributors, and payers have shifted to alternatives.
What Paragraph IV challenges and litigation affect the market?
Paragraph IV litigation is product-specific and cannot be inferred solely from the age of the active ingredients. A generic applicant may certify that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The resulting litigation could delay approval or create a 30-month stay, depending on the timing and statutory requirements.
For lidocaine-tetracaine, litigation risk is more likely to center on:
- formulation claims;
- patch architecture;
- controlled-release mechanisms;
- manufacturing processes;
- patent-listing eligibility;
- obviousness of combining known anesthetics in a known topical vehicle.
The commercial impact of litigation is limited where multiple non-infringing alternatives exist. A patent dispute affecting one branded patch does not necessarily protect the broader combination market.
What is the financial trajectory for lidocaine-tetracaine?
Standalone revenue is generally not disclosed by manufacturers because lidocaine-tetracaine sales are usually embedded within broader topical-anesthetic or specialty-pharmaceutical portfolios. The financial trajectory is therefore best assessed through market structure rather than reported product revenue.
| Financial driver |
Directional impact |
| Generic cream entry |
Reduces price and branded share |
| Proprietary patch technology |
Supports higher net price |
| Dermatology and aesthetic procedures |
Expands demand |
| Pediatric and vascular-access use |
Supports recurring institutional demand |
| Reimbursement restrictions |
Pressures utilization and price |
| Manufacturing complexity |
Raises cost but can slow competitors |
| Brand discontinuation or supply interruption |
Creates temporary share opportunities |
| Lidocaine-only substitution |
Limits combination growth |
The base case is mature, low-to-moderate growth with declining unit economics for conventional cream and better margin potential for differentiated delivery systems. Revenue can rise in procedure-heavy dermatology and aesthetic markets, but that growth is unlikely to produce strong exclusivity unless a company controls a defensible delivery platform.
What generic launch scenarios exist?
Three launch scenarios are commercially plausible.
Conventional generic cream
This is the highest-probability scenario. Entry would target price-sensitive prescriptions and institutional buyers. The principal advantage is lower cost. The main weakness is limited differentiation from other topical anesthetics.
Complex generic or authorized alternative
A manufacturer could pursue a formulation that approximates the branded cream's film-forming or application characteristics. Development would take longer and require more formulation work, but the product could command a modest premium over ordinary cream.
Patch or device-enabled competitor
A patch competitor faces the greatest development burden. It must replicate drug delivery, adhesion, heating, packaging, and user handling. If successful, it could compete for procedure settings where convenience supports premium pricing.
What licensing deals affect the product category?
Pliaglis and Synera have historically involved specialty-product development and commercialization arrangements rather than broad platform licensing. The principal commercial value in such deals lies in rights to a finished product, formulation technology, or delivery system.
Deal economics typically depend on:
- territory;
- regulatory status;
- manufacturing responsibility;
- minimum purchase commitments;
- transfer pricing;
- milestones;
- royalties;
- rights after discontinuation;
- control of patent enforcement.
No single licensing transaction determines the market's financial trajectory. Product-level licensing is more relevant to individual brands than to the lidocaine-tetracaine category.
How strong is the patent estate for lidocaine-tetracaine?
The patent estate is weak at the molecule level and potentially moderate for specific delivery systems. A conventional 7%/7% cream is exposed to formulation design-around and substitution. A proprietary patch or film product can retain stronger protection if its claims cover the integrated system and remain difficult to design around.
The strongest commercial protections are likely to be:
- regulatory familiarity and physician adoption;
- manufacturing know-how;
- product-specific delivery performance;
- supply reliability;
- distribution relationships;
- remaining formulation or device patents.
Patent protection alone is unlikely to support durable category-wide pricing power.
What biosimilar risk exists?
Biosimilar risk is not applicable. Lidocaine and tetracaine are small-molecule active ingredients, not biologics. Competition proceeds through generic-drug, abbreviated-application, formulation, device, and substitution pathways rather than the FDA biosimilar pathway.
Key Takeaways
- Lidocaine-tetracaine is a mature topical-anesthetic combination with no meaningful new-chemical-entity exclusivity.
- Pliaglis and Synera are the principal branded reference products associated with the combination.
- Commercial differentiation depends on cream, film, patch, heating, adhesion, and application performance.
- Generic pressure is high for conventional cream products.
- Patch and film formulations can retain greater commercial value because they are harder to reproduce.
- Orange Book and Paragraph IV analysis must be performed by NDA and dosage form, not for the combination as a whole.
- Biosimilar risk does not apply.
- Standalone revenue is generally not disclosed, making category-level unit economics more useful than company-reported product sales.
- The base financial outlook is mature and price-sensitive, with selective premium opportunities in dermatology, aesthetics, pediatric care, and procedural medicine.
FAQs
Is lidocaine-tetracaine cream available over the counter?
Some lidocaine products are sold over the counter, but prescription lidocaine-tetracaine combinations such as Pliaglis are regulated separately. OTC availability depends on the specific product, strength, labeling, and jurisdiction.
Is Pliaglis the same as EMLA?
No. Pliaglis contains lidocaine and tetracaine. EMLA contains lidocaine and prilocaine. They use different active ingredients and may have different onset, application, and regulatory characteristics.
Can a generic manufacturer copy the Pliaglis formulation?
A manufacturer may develop a pharmaceutically equivalent or therapeutically equivalent product, subject to FDA requirements and any unexpired, enforceable patents. The manufacturer must address formulation performance, drug release, stability, and application characteristics.
Does lidocaine-tetracaine have a biosimilar competitor?
No. Biosimilars apply to biological products. Lidocaine-tetracaine products compete through generic-drug and formulation pathways.
Which market has the greatest growth potential for lidocaine-tetracaine?
Procedure-driven dermatology, aesthetic medicine, pediatric needle procedures, and vascular-access applications have the strongest potential. Growth is constrained by substitution from lidocaine-only products, lidocaine-prilocaine products, injections, and non-drug anesthetic devices.
References
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2005). Synera prescribing information.
- U.S. Food and Drug Administration. (2006). Pliaglis prescribing information.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
- U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and generic drug patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/paragraph-iv-certifications
- U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/biosimilars/biosimilar-biological-products
